Inmunoterapia en 1L del CPCNP: monoterapia y/o tratamiento combinado - page 6

1L NSCLC: Keynote 024

Reck M, et al. NEJM 2016

NR both arms

70% vs 54% 1y

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4,5 7,8,9,10,11,12,13,14,15,16,...42